Hill-Rom Holdings, Inc. (NYSE:HRC) Given Consensus Rating of “Buy” by Brokerages

Shares of Hill-Rom Holdings, Inc. (NYSE:HRC) have received a consensus rating of “Buy” from the eight brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $124.00.

Several brokerages recently commented on HRC. Robert W. Baird assumed coverage on shares of Hill-Rom in a report on Tuesday, September 1st. They issued an “outperform” rating and a $115.00 target price on the stock. Morgan Stanley dropped their price objective on Hill-Rom from $123.00 to $112.00 and set an “overweight” rating on the stock in a research note on Monday, August 3rd. Raymond James restated a “buy” rating on shares of Hill-Rom in a research note on Wednesday. KeyCorp dropped their price target on Hill-Rom from $140.00 to $138.00 and set an “overweight” rating on the stock in a research report on Monday, August 3rd. Finally, Needham & Company LLC cut their price target on Hill-Rom from $131.00 to $129.00 and set a “buy” rating for the company in a report on Friday, July 31st.

In other news, SVP Mary Kay Ladone sold 2,278 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $110.00, for a total transaction of $250,580.00. Following the sale, the senior vice president now directly owns 8,163 shares in the company, valued at $897,930. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.65% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of the company. Citizens Financial Group Inc RI boosted its holdings in Hill-Rom by 42.0% during the second quarter. Citizens Financial Group Inc RI now owns 1,032 shares of the medical technology company’s stock valued at $113,000 after purchasing an additional 305 shares in the last quarter. Natixis Advisors L.P. boosted its stake in Hill-Rom by 7.0% in the 2nd quarter. Natixis Advisors L.P. now owns 41,088 shares of the medical technology company’s stock valued at $4,511,000 after buying an additional 2,705 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Hill-Rom by 36.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,149 shares of the medical technology company’s stock valued at $619,000 after acquiring an additional 1,641 shares during the period. Royal Bank of Canada raised its stake in Hill-Rom by 23.2% during the first quarter. Royal Bank of Canada now owns 16,542 shares of the medical technology company’s stock worth $1,663,000 after acquiring an additional 3,115 shares in the last quarter. Finally, Nordea Investment Management AB raised its stake in Hill-Rom by 100.0% during the second quarter. Nordea Investment Management AB now owns 105,946 shares of the medical technology company’s stock worth $11,466,000 after acquiring an additional 52,979 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Shares of HRC stock opened at $84.49 on Thursday. The stock’s 50 day simple moving average is $94.51 and its 200 day simple moving average is $101.16. Hill-Rom has a twelve month low of $72.29 and a twelve month high of $117.68. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.16 and a current ratio of 1.50. The company has a market capitalization of $5.63 billion, a price-to-earnings ratio of 27.25, a PEG ratio of 2.71 and a beta of 0.59.

Hill-Rom (NYSE:HRC) last announced its quarterly earnings results on Friday, July 31st. The medical technology company reported $1.95 EPS for the quarter, beating the consensus estimate of $1.46 by $0.49. Hill-Rom had a return on equity of 25.48% and a net margin of 7.05%. The company had revenue of $767.50 million for the quarter, compared to the consensus estimate of $749.39 million. During the same quarter last year, the company posted $1.23 earnings per share. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. On average, analysts forecast that Hill-Rom will post 5.45 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Friday, September 18th will be given a $0.22 dividend. The ex-dividend date is Thursday, September 17th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 1.04%. Hill-Rom’s dividend payout ratio is currently 17.32%.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Featured Article: Quiet Period Expirations Explained

Analyst Recommendations for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply